Arrowhead Pharmaceuticals, Inc. (ARWR) — closed signal from February 18, 2026
Target reached Published before the outcome was known, scored automatically when the window closed on May 19, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published February 18, 2026
Short-term trade idea over the next 0-3 months based on company updates. Early signs show the new REDEMPLO product is starting to sell, and the company has more flexible funding options that lessen the chance it must issue lots of new shares. That combination focuses attention back on clinical and launch progress. Biotech news can move the stock sharply, so watch momentum before adding.
Primary drivers
- Early REDEMPLO sales suggest commercialization is beginning
- Better funding terms lower the chance of big share dilution
- Upcoming clinical or approval news can quickly change valuation
- Biotech headlines can cause sudden gaps; enter in stages
How it played out
ARWR: target stayed out of reach
Lyra published ARWR at 64.69 on 2026-02-18 as a short-term trade idea for 0-3 months. The thesis expected 28% growth and pointed to early REDEMPLO sales, better funding terms that could lower dilution risk, and possible clinical or approval news. It also warned that biotech headlines could cause sudden gaps.
Inside the window, ARWR rose as high as 82 on 2026-05-14, a 26.8% peak gain. That stayed below the 82.8 target, so the target was never reached. The stock ended the window at 73.18 on 2026-05-19. The thesis largely played out on direction and scale, but it missed the stated target.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.